+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07143669

Multicenter Screening to Identify KIT D816V Mutation Prevalence in Patients Suspected of Clonal Mast Cell Disease

Led by Blueprint Medicines Corporation · Updated on 2026-10-07

750

Participants Needed

26

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a multicenter screening study to determine how common the KIT D816V mutation is among people suspected of having clonal mast cell disease. This study focuses on various groups, including those with symptoms of mast cell activation, certain related diseases, specific blood cancers, and skin mast cell involvement. Participants are divided into four cohorts based on their symptoms or diagnoses. The study involves collecting blood or bone marrow samples after informed consent and medical history review. The main goal is to detect the KIT D816V mutation in peripheral blood using advanced molecular techniques on the first day of participation. During the study, participants provide samples and relevant health information. Researchers measure the presence of the mutation using digital droplet PCR and a super rolling circle amplification assay. The study continues until July 2028, with follow-up evaluations focusing on mutation prevalence to better understand this condition.

CONDITIONS

Brief Title

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Research Team

B

Blueprint Medicines

B

Blueprint Medicines, EU Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here